Wells Fargo analyst Lawrence Biegelsen upgraded Medtronic to Outperform from Market Perform and raised his price target for the shares to $110 from $100. The stock closed today up $1.08 to $94.41. The analyst says the company’s late stage pipeline will accelerate its growth into fiscal 2021. Further, management has done a better job over the past year of managing consensus expectations, Biegelsen tells investors in a research note. Medtronic is an “accelerating growth story trading at a steep discount to peers,” adds the analyst, who sees the valuation gap closing as its growth picks up.